Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice

• Main Authors: Andras Franko (Author), Susanne Neschen (Author), Jan Rozman (Author), Birgit Rathkolb (Author), Michaela Aichler (Author), Annette Feuchtinger (Author), Laura Brachthäuser (Author), Frauke Neff (Author), Marketa Kovarova (Author), Eckhard Wolf (Author), Helmut Fuchs (Author), Hans-Ulrich Häring (Author), Andreas Peter (Author), Martin Hrabě de Angelis (Author)
• Format: Book
• Published: Elsevier, 2017-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: Recently, we have shown that Bezafibrate (BEZ), the pan-PPAR (peroxisome proliferator-activated receptor) activator, ameliorated diabetes in insulin deficient streptozotocin treated diabetic mice. In order to study whether BEZ can also improve glucose metabolism in a mouse model for fatty...